In summary, this study provides compelling preclinical evidence supporting the therapeutic potential of bone-targeted PTHrP antagonists, PTH(7-33)-CBD and [W2]PTH(1-33)-CBD, in inhibiting breast cancer bone metastases. Here, PTHLH is linked to breast cancer.